Report
Valens Research

TXG - Embedded Expectations Analysis - 2022 05 19

10x Genomics (TXG) currently trades at a premium relative to Uniform assets, with a 3.4x Uniform P/B (V/A').

At these levels, markets are pricing in expectations for Uniform ROA to expand to 11%, accompanied by 12% Uniform asset growth.

Similarly, analysts expect Uniform ROA to improve to 6% in 2023, accompanied by 24% Uniform asset growth.

If sustained going forward, these levels would imply a stock price closer to $38, representing approximately 20% potential equity downside for the firm.

Moreover, the firm's most recent earnings call suggests management may have concerns about growth opportunities, Chromium X Series, and product lines.
Underlying
10x Genomics Inc Class A

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch